*Arbutus shares are trading higher after The Patent Trial and Appeals Board has turned down Moderna's appeal to invalidate two of Arbutus' patents on drug-delivery technology. Benzinga
also 12-01-2021
$ABUS Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity December 01 2021 - 11:58AM GlobeNewswire Inc. Alert Print Share On Facebook
ABUS 1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension. 2) May 5th. HBV Virtual Summit 3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020 4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th 5) Annual Meeting email sent April 22nd. Meeting May 23rd 6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020. 7) Announced $75M Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021. OS rose from 85M to 96M 8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago. 24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares. 9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares 10) Sophie developed cure for HepC! 11) Pipeline!!! AB 729 PT COVID P1 ends 4/30 12) Gritstone 13) Genevant
AND; $ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!
MRNA MarketWatch • 2 hours ago U.S. buys another 100 million COVID-19 vaccine candidate doses: Moderna IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.